By Michele Maatouk
Date: Thursday 10 Oct 2019
(Sharecast News) - Belgian drug maker UCB has agreed to buy US-based clinical-stage biopharmaceuticals company Ra Pharmaceuticals for $2.1bn.
No recent information was found.
| GSK gets emerging markets boost with UCB deal | 24-Jan-2009 | Telegraph |
| UCB confident on drug go-ahead | 21-Aug-2007 | The Scotsman |
| Fellner shuffles Acambis board | 08-Mar-2007 | Telegraph |
| Deal speeds drugs sector consolidation | 26-Sep-2006 | The Herald |
No recent information was found.
No recent information was found.
| Currency | Euro |
| Share Price | 260.60 |
| Change Today | 5.20 |
| % Change | 2.04 % |
| 52 Week High | 265.60 |
| 52 Week Low | 129.35 |
| Volume | 142,229 |
| Shares Issued | 190.00m |
| Market Cap | 49,514m |
| Beta | 2.26 |
| Strong Buy | 6 |
| Buy | 11 |
| Neutral | 3 |
| Sell | 0 |
| Strong Sell | 1 |
| Total | 21 |

| Time | Volume / Share Price |
| 17:35 | 35 @ 260.60 |
| 17:35 | 500 @ 260.60 |
| 17:35 | 128 @ 260.60 |
| 17:35 | 533 @ 260.60 |
| 17:35 | 117 @ 260.60 |
You are here: research